KINACEPT

Novel anti-inflammatory compounds for autoimmune diseases

 Coordinatore SYNOVO GMBH 

 Organization address address: Paul Ehrlich Str 15
city: TUEBINGEN
postcode: 72076

contact info
Titolo: Dr.
Nome: Michael
Cognome: Burnet
Email: send email
Telefono: 0049 7071 600543
Fax: 0049 7071 964326

 Nazionalità Coordinatore Germany [DE]
 Sito del progetto http://www.medizin3.uk-erlangen.de/e1846/e623/e719/index_ger.html
 Totale costo 1˙475˙995 €
 EC contributo 1˙041˙700 €
 Programma FP7-SME
Specific Programme "Capacities": Research for the benefit of SMEs
 Code Call FP7-SME-2007-1
 Funding Scheme BSG-SME
 Anno di inizio 2008
 Periodo (anno-mese-giorno) 2008-12-01   -   2010-11-30

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    SYNOVO GMBH

 Organization address address: Paul Ehrlich Str 15
city: TUEBINGEN
postcode: 72076

contact info
Titolo: Dr.
Nome: Michael
Cognome: Burnet
Email: send email
Telefono: 0049 7071 600543
Fax: 0049 7071 964326

DE (TUEBINGEN) coordinator 0.00
2    CAIR BIOSCIENCES GMBH

 Organization address address: PAUL EHRLICHSTRASSE 15
city: TUBINGEN
postcode: 72076

contact info
Titolo: Dr.
Nome: Wolfgang
Cognome: Albrecht
Email: send email
Telefono: 0049 7071 9652081
Fax: 0049 7071 9652089

DE (TUBINGEN) participant 0.00
3    EBERHARD KARLS UNIVERSITAET TUEBINGEN

 Organization address address: GESCHWISTER-SCHOLL-PLATZ
city: TUEBINGEN
postcode: 72074

contact info
Titolo: Prof.
Nome: Stefan
Cognome: Laufer
Email: send email
Telefono: 0049 7071 2972459
Fax: 0049 7071 295037

DE (TUEBINGEN) participant 0.00
4    EPISTEM LTD

 Organization address address: GRAFTON STREET INCUBATOR BLDG 48
city: MANCHESTER
postcode: M13 9XX

contact info
Titolo: Mr.
Nome: John
Cognome: Rylands
Email: send email
Telefono: +44 (0)161 606 7258
Fax: +44 (0)161 606 7348

UK (MANCHESTER) participant 0.00
5    FRIEDRICH-ALEXANDER-UNIVERSITAT ERLANGEN NURNBERG

 Organization address address: SCHLOSSPLATZ 4
city: ERLANGEN
postcode: 91054

contact info
Titolo: Prof.
Nome: Georg
Cognome: Schett
Email: send email
Telefono: 0049 9131 8533418
Fax: 0049 8534770

DE (ERLANGEN) participant 0.00
6    INTE:LIGAND SOFTWARE-ENTWICKLUNGS- UND CONSULTING GMBH

 Organization address address: Clemens-Maria Hofbauer Gasse 6
city: MARIA ENZERSDORF
postcode: 2344

contact info
Titolo: Prof.
Nome: Langer
Cognome: Thierry
Email: send email
Telefono: 0043 6991 5075252
Fax: 0043 1 8174955 1371

AT (MARIA ENZERSDORF) participant 0.00
7    QUEEN MARY UNIVERSITY OF LONDON

 Organization address address: 327 MILE END ROAD
city: LONDON
postcode: E1 4NS

contact info
Titolo: Dr.
Nome: Michael
Cognome: Seed
Email: send email
Telefono: 0044 7973 307726
Fax: 0044 207 8826095

UK (LONDON) participant 0.00
8    ROBERT BOSCH GESELLSCHAFT FUR MEDIZINISCHE FORSCHUNG MBH

 Organization address address: AUERBACHSTRASSE 112
city: STUTTGART
postcode: 70376

contact info
Titolo: Prof.
Nome: Matthias
Cognome: Schwab
Email: send email
Telefono: 0049 711 8101 3700
Fax: 0049 711 859295

DE (STUTTGART) participant 0.00
9    UNIVERSITA DEGLI STUDI DI PERUGIA

 Organization address address: PIAZZA DELL' UNIVERSITA 1
city: PERUGIA
postcode: 6123

contact info
Titolo: Prof.
Nome: Stefano
Cognome: Fiorucci
Email: send email
Telefono: 0039 755783883
Fax: 0039 75573883

IT (PERUGIA) participant 0.00
10    USTAV MOLEKULARNI GENETIKY AKADEMIE VED CESKE REPUBLIKY VEREJNA VYZKUMNA INSTITUCE

 Organization address address: VIDENSKA 1083
city: PRAHA 4
postcode: 142 20

contact info
Titolo: Prof.
Nome: Vladimir
Cognome: Holan
Email: send email
Telefono: 00420 241 063 226
Fax: 00420 224 310 955

CZ (PRAHA 4) participant 0.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

select    arthritis       compounds    expression    clinical    trials    inflammatory    tissue    anti    conduct    ibd    indicated    rheumatoid    explant    sect    stratification    inhibitors    pre    models    therapy    patient    class    disease    responders   

 Obiettivo del progetto (Objective)

'The consortium has a lead series of p38 inhibitors with unusual anti-inflammatory properties. The drug leads were originally elaborated as a potential therapy for inflammatory bowel disease, however, the potency of the compounds and their general anti-inflammatory mode of action has raised the possibility of studying their utility in other diseases including rheumatoid arthritis. In addition, feedback from licensing partners has indicated that clear activity in a range of other disease models would dramatically increase interest. A key issue in bringing substances of this class to the clinic is variable patient response to p38 inhibitors in previous trials. Data to date have indicated that there is a potential groups of responders for whom therapy with this class is highly beneficial. The effect of non-responders has, however, made trial outcomes to variable to warrant further development. To solve this problem, we intend to further extend proof-of-concept in patient stratification to allow us to select responder populations for initial patient trials. The objectives of the project are, therefore: § To prepare analogs of the existing compounds § Conduct pre-clinical models for rheumatoid arthritis, IBD, sepsis, liver fibrosis and motilin dependent gut stimulation § Examine the activity of the compounds in human tissue explant models § Select a pre-clinical candidate class § Develop a scaled-up process for GMP synthesis of the lead § Conduct a survey of p38 expression in IBD and RA sub-types at various stages of disease and correlate this plasma markers. § Based on results of tissue explant studies and p38 expression, select a patient stratification protocol for phase 2A studies in man.'

Altri progetti dello stesso programma (FP7-SME)

LOWASH (2012)

Low Energy Washer Dryer through the Development of an Innovative Load Balancing & High Efficient Heat Recovery System

Read More  

ALTITUDE (2014)

"ALTernative to Indium Tin Oxide materials for sustainable growth of displays, solar and automobile industries"

Read More  

MARKET IT (2012)

Demonstrating the industrial validity and market feasibility of IT Tool to support SMEs in systematic innovation processes

Read More